

16 October 2024

Twist Bioscience attests that the company adheres to all requirements in the U.S. OSTP [Framework for Nucleic Acid Synthesis Screening](#). Twist implements the following critical biosecurity and information security practices, as specified in the Framework:

- Screens purchase orders for synthetic nucleic acids to identify sequences of concern (SOCs)
- Screens customers submitting purchase orders of synthetic nucleic acids with SOC to verify legitimacy
- Reports potentially illegitimate purchase orders of synthetic nucleic acids involving SOC to relevant authorities
- Retains records relating to purchase orders for synthetic nucleic acids
- [Takes steps](#) to ensure cybersecurity and information security including ISO 27001 certification.

Any questions on Twist's biosecurity practices may be addressed to [biosecurity@twistbioscience.com](mailto:biosecurity@twistbioscience.com).

Twist is committed to satisfying the requirements of the OSTP Framework. In the unlikely event that our adherence status changes, Twist commits to notifying, within 72 hours, any federally funded customers and federal funding agencies to which we have previously submitted an attestation.

Signed,



Emily Leproust  
CEO & Co-Founder  
Twist Bioscience